Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
February 13, 2015 8:29 AM ESTRoth Capital comments on Cytokinetics (Nasdaq: CYTK) following Q4, FY14 results reported late Thursday. The firm retains a Buy rating and $18 price target on Cytokinetics following the numbers and update.
Analyst Joseph Pantginis noted that Cytokinetics reported FY14 loss of $0.41 per share with revenue of $46.9 million, versus the firm's... More
Piper Jaffray Upgrades Cytokinetics (CYTK) to Overweight; Sees 100% Upside
February 13, 2015 6:46 AM ESTPiper Jaffray upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to Overweight with a price target of $13.00 (from $7.00), suggesting 100% upside from current levels.
Analyst Charles Duncan commented, "Cytokinetics reported 4Q/FY14 results yesterday, ending '14 with $83M in cash which combined with inflows already in '15... More
